Breaking News

Tweet TWEET

Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013

Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results
                         on Tuesday, August 13, 2013

PR Newswire

NANJING, China, July 29, 2013

NANJING, China, July 29, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group
(NYSE: SCR), a leading pharmaceutical company specializing in the development,
manufacturing, and marketing of branded generic and proprietary
pharmaceuticals in China, today announced that it will report its unaudited
financial results for the second quarter ended June 30, 2013 on Tuesday,
August 13, 2013, before the market opens in the United States. Simcere's
management will host an earnings conference call on the same day at 8 a.m. ET
(Tuesday, August 13 at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

International toll:         +65.6723.9381
United States toll-free:    +1.866.519.4004
United States toll:         +1.845.675.0437
China Domestic toll:        800.819.0121
China Domestic mobile toll: 400.620.8038
Hong Kong toll:             +852.2475.0994

Please ask to be connected to Q2 2013 Simcere Pharmaceutical Group Earnings
Conference Call and provide the following passcode: 23263347.

Simcere will also broadcast a live audio webcast of the conference call. The
broadcast will be available by visiting the "Investor Relations" section of
the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be
available by dialing:

United States toll-free: +1. 855.452.5696
United States toll:      +1. 646.254.3697

The passcode for replay participants is 23263347. The telephone replay also
will be archived on the "Investor Relations" section of the company's website
for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical
company specializing in the development, manufacturing, and marketing of
branded and proprietary pharmaceuticals in China. Simcere concentrates its
research and development efforts on the treatment of diseases with high
incidence and/or mortality rates and for which there is a clear demand for
more effective pharmacotherapy such as cancer, strokes, cardiovascular
disease, infectious diseases and pain. For more information about Simcere
Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:
Jie Liu D'Elia               In the United States:
Vice President
Simcere Pharmaceutical Group Cindy Zheng

Tel: 86-25-8556-6666*8857    Brunswick Group

                            Tel: 1-212-333-3810

In Beijing:                  
Yue Yu
                             
Brunswick Group
                             
Tel: 86-10-5960-8600

SOURCE Simcere Pharmaceutical Group

Website: http://www.simcere.com